Analysis of the experience of using insulin therapy with the closed loop method among patients with type 1 diabetes in Russia
AbstractThe relevance of the study is due to the growing prevalence of pump insulin therapy using the closed loop method in the world.
The aim - to evaluate the efficiency and safety of using closed loop systems in patients with type 1 DM living in Russia.
Material and methods. the study included 81 respondents (or their legal representatives) with type 1 DM receiving insulin therapy using the closed-loop system, consisting of Russian-speaking communities on the Internet. Questionnaire of respondents was conducted using the "Survey for patients with type 1 diabetes mellitus undergoing closed loop therapy".
Results and discussion. Most of respondents (90%) living in Russia. All respondents using do-it-yourself artificial pancreas systems (DIYAPS): Loop (18.5%), OpenAPS (32.1%) and AndroidAPS (49.4%). Hlycated haemoglobin was normal in 92% of cases of using DIYAPS. 89% of respondents notice improvement of glycemic control. Among the advantages of closed loop therapy, respondents noted an increase time-in-range (78% of respondents), a decrease in the frequency of mild hypoglycemia (60% of respondents), a decrease in the frequency of severe hypoglycemia (58% of respondents), and improved glycemic control at night (94% of respondents).
Conclusions. The use of pump insulin therapy using closed loop systems leads to a decrease in the level of glycated hemoglobin by 0.5% (p=0.01) compared with the use of standard pump insulin therapy. The majority (78%) of type 1 DM respondents receiving closed-loop pump insulin therapy noted an increase in the time-in-range compared to standard pump insulin therapy. The use of closed-loop systems is associated with a decrease in the frequency of mild (in 60.5% of respondents) and severe hypoglycemic conditions (in 58% of respondents) compared to standard pump insulin therapy in respondents with type 1 DM.
Keywords:closed loop system, type 1 diabetes mellitus, insulin pump therapy
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
Contribution. All authors are co-executors of the study and have made an equal contribution to the development of its concept and design, as well as to data analysis and interpretation of results. Also all of them reviewed manuscript drafts and have approved the final version for submission.
For citation: Volkova A.R., Chernaya M.E., Lisker A.V., Vlasova K.A. Analysis of the experience of using insulin therapy with the closed loop method among patients with type 1 diabetes in Russia. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 35-41. doi: 10.33029/2304-9529-2020-9-1-35-41 (in Russian)
References
1. Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363: 311-20. doi: 10.1056/NE-JMoa1002853
2. Battelino T., Danne T., Bergenstal R.M., et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019; 42 (8): 1593-603. doi: 10.2337/dci19-0028
3. Volkova A.R., Chernaya M.E., Lisker A.V., Sokolova M.N., Fedulova Zh.V. Glycemic variability in patients with type 1 diabetes mellitus with different types of insulin therapy. Endokrinologiya: novosti, mneniya, obu-chenie [Endocrinology: News, Opinions, Training]. 2019; 8 (3): 38-43. doi: 10.24411/2304-9529-2019-13004 (in Russian)
4. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., et al. Diabetes epidemiology in Russia: what has changed over the decade? Terapevtich-eskiy arkhiv [Therapeutic Archive]. 2019; 91 (10): 4-13. doi: 10.26442/00 403660.2019.10.000364 (in Russian)
5. Uduku C., Oliver N. Pharmacological aspects of closed loop insulin delivery for type 1 diabetes. Curr Opin Pharmacol. 2017; 36: 29-33. doi: 10.1016/j.coph.2017.07.006
6. Brown S.A., Kovatchev B.P., Raghinaru D. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019; 381: 1707-17. doi: 10.1056/NEJMoa1907863
7. Allen N., Gupta A. Current diabetes technology: striving for the Artificial pancreas. BMJ Open. 2019; 9 (6): e027856. doi: 10.1136/bm-jopen-2018-027856
8. Bekiari E., Kitsios K., Thabit H., et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018; 361. doi: https://doi.org/10.1136/bmj.k1310
9. Russell S.J., El-Khatib F.H., Sinha M., Magyar K.L., McKeon K., Goergen L.G., et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014; 371: 313-25. doi: 10.1056/NEJMoa1314474
10. El-Khatib F.H., Balliro C., Hillard M., Magyar K.L., Ekhlaspour L., Sinha M., et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017; 387: 369-80. doi.org/10.1016/S 0140-6736(16)32567-3
11. Sherr J.L., Buckingham B.A., Forlenza G.P., Galderisi A., Ekhlaspour L., Wadwa R.P., et al. Safety and performance of the omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions. Diabetes Technol Ther. 2020; 22 (3): 174-84. doi: 10.1089/dia.2019.0286
12. Braune K., O’Donnell S., Cleal B., Lewis D., Tappe A., Willaing I., et al. Real-world use of do-it-yourself artificial pancreas systems in children and adolescents with type 1 diabetes: online survey and analysis of selfreported clinical outcomes. JMIR Mhealth Uhealth. 2019; 7 (7): e14087. doi: 10.2196/14087
13. Forlenza G.P, Buckingham B.A., Christiansen M.P., Wadwa R.P., Peyser T.A., Lee J.B., et al. Performance of omnipod personalized model predictive control algorithm with moderate intensity exercise in adults with type 1 diabetes. Diabetes Technol Ther. 2019; 21 (5): 265-72. doi: 10.1089/ dia.2019.0017
14. Thabit H., Tauschmann M., Allen J.M., Leelarathna L., Hartnell S., Wilinska M.E., et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015; 373 (22): 2129-40. doi: 10.1056/NEJMoa1509351
15. Haidar A., Legault L., Dallaire M., Alkhateeb А., Coriati A., Messier V., et al. Glucose-responsive insulin and glucagon delivery (dualhormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013; 185 (4): 297-305. doi: 10.1503/ cmaj.121265
16. Kovatchev B.P., Renard E., Cobelli C., Zisser H.C., Keith-Hynes P, Anderson S.M., et al. Safety of outpatient closed-Loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014; 37 (7): 1789-96. https://doi.org/10.2337/dc13-2076